VEGFA and neoplasm: Inhibition of the VEGF pathway using the VEGF antibody bevacizumab as either single or combination therapy has become an established clinical anti-angiogenic treatment regimen applied in various tumor entities, including non-small-cell lung, colorectal, and breast cancer [13].